CORD-19:12d35c12218f230c49f4dc892814ba9f1037f251 / 61451-61674 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/12d35c12218f230c49f4dc892814ba9f1037f251","sourcedb":"CORD-19","sourceid":"12d35c12218f230c49f4dc892814ba9f1037f251","text":"To this end, toxicity trials in non-human primates have already demonstrated that agonistic OX40 antibody therapy is well tolerated and safe, therefore providing a strong rationale to pursue clinical tests in humans (168) .","tracks":[{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T55","span":{"begin":0,"end":223},"obj":"Sentence"}],"attributes":[{"subj":"T55","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-Sentences","denotations":[{"id":"T22135","span":{"begin":0,"end":223},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T22135","pred":"source","obj":"CORD-19-Sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19_Custom_license_subset","color":"#ec93a5","default":true},{"id":"CORD-19-Sentences","color":"#93bfec"}]}]}}